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Abstract
The use of historical estimates in current studies is common in a wide variety of application areas. Neverthe-
less, despite their routine use the uncertainty associated with historical estimates is rarely properly accounted
for in the analysis. In this communication we review common practices and then provide a mathematical
formulation and a principled methodology for addressing the problem of drawing inferences in the presence
of historical data. Three distinct variants are investigated in detail; the corresponding limiting distributions
are found and compared. The design of future studies, given historical data, is also explored and relations
with a variety of other well–studied statistical problems discussed.
Keywords: Bliss–independence, Double–sampling, Loewner order.
1. Introduction
There are many circumstances in which a statistical analysis either requires, or can greatly benefit, from
the use of historical data. Often, the historical data consists of parameter estimates, which are essential for
model fitting but impossible, or very expensive, to collect in the context of the current study. As reviewed
below historical data are used in a variety of applications in the social, physical, and biomedical sciences.
The planning of early detection programs for breast, prostate or other cancers requires knowledge of the
sojourn time distributions in the healthy, pre–clinical, and clinical states. The sojourn times, however, are not
directly observed, rather their convolution, i.e, the overall incidence rate is observed. Cancer incidence rates
are collected by various cancer agencies and registries such as the Surveillance, Epidemiology and End Results
(SEER) registry maintained by the US National Cancer Institute (https://seer.cancer.gov/registries/). Given
the overall incidence rate and the estimated values of some parameters all sojourn time distributions can be
then estimated by deconvolution. See Lee and Zelen (1998) and Davidov and Zelen (2004) for further details.
It is worth noting that the application above may be viewed as a model for situations in which knowledge
collected in one setting, experimental or observational, is then used to estimate quantities arising in a different
experiment and is quite common in the biomedical sciences. For example, some models for the spread of
infectious diseases, such as the SIR model (Becker, 2017) require the input of age specific transmission
parameters which can be estimated from social contact networks (Edmunds et al. 1997, Wallinga et al.
2006) and then used to fit epidemic models (Mossong et al. 2008, Goeyvaerts et al. 2010, Yaari et al. 2016).
Another interesting application is the optimization of cancer treatment where Kronick et al. (2010) develop a
framework for predicting the outcome of prostate cancer immunotherapy by fitting personalized mathematical
models. Their model consists of a set of differential equations whose behavior is governed by a collection of
parameters, some of which are global parameters while others are subject specific. The values of the global
parameters were obtained from at least ten different published studies, see their Table 2, whereas the subject
level parameters were estimated by fitting a model to each participant assuming that the global parameters
were estimated without error. See Kogan et al. (2012) and Koz lowska et al. (2018) for a similar applications.
Another very important application in which historical data is used is clinical trials. Consider, for example,
the situation in which the effect of a combination of treatments is assessed (e.g., Tamma et al. 2012, Kandra
et al. 2016). In such cases there exists a collection of therapies which have been independently proven to be
somewhat successful at treating a medical condition. The objective of a new study may then be to assess
whether a combination of these therapies provides an even better outcome. In the simplest case, one may
view this problem as a three armed clinical trial comparing treatments A,B and A+B in which historical
data on treatments A and B already exists. An important example of such situations is the Federal Drug
Administration (2006) guidelines for submitting applications for approval of fixed dose combinations, i.e.,
co–packaged drug products, of previously approved antiretrovirals for the treatment of HIV. In particular,
Attachment A of the aforementioned document considers the scenario in which a non–innovator, i.e., a generic
drug company, wants to obtain approval for a combination of already approved ingredients. In this case,
only efficacy data for the combination needs to be submitted. We will revisit and thoroughly analyze two
forms of this example later on. More broadly, the use of historical data in the contexts of clinical trials has
been investigated by numerous researchers and multiple perspectives, cf., Pocock (1976), Peto et al. (1979),
Neuenschwander et al. (2010), Viele et al. (2014), and Piantadosi (2017) among many others.
The use of historical estimates is also widespread in the social sciences. For example, in the fitting
of some econometric models researchers may use values estimated from previously collected survey data.
The complexity of using historical estimates in the social sciences is well illustrated by the work of Tasseva
(2019). In a microsimulation study investigating the effect of the recent expansion in higher education in
Great Britain on household inequalities, previously obtained estimates of population figures from the Family
Resources Survey for Great Britain (GOV.UK 2019) were used. The study used bootstrap methods in an
effort to account for sampling variability in the survey data. But as noted by the author this method does not
appropriately account for measurement error, inevitably present in income information collected in surveys,
see, e.g., Moore et al. (2000). Similarly, Douidich et al. (2015) describe an imputation–related–method
for incorporating estimates obtained in labor force surveys (which are easily and cheaply conducted) into
household expenditure surveys (which are much more time consuming and expensive) in order to estimate
poverty rates in Morocco. Likewise, demographic model fitting and projections rely on historical data. The
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standard method of population projections (see United Nations, 2014) is based on the combination of cohort
survival rates, i.e., historical data, with current data on cohort sizes. Raftery et al. (2014) proposed a
Bayesian approach to take the uncertainty associated with historical data into account. It is worth noting
that in this case the uncertainty accounted for by the Bayesian modelling did not come from observational
errors but rather from the fact, that the true population figures may have changed over time.
We observe that researchers often do not adequately account for the variability of the historical estimators
when incorporating them into a current analysis. In fact, we believe that the practice of plugging–in the
estimated values for certain parameters is widespread. Nevertheless it is poorly accounted for, nor properly
reported on, in the literature as most practitioners view this strategy as a natural way of ”doing things”.
Therefore, the objectives of this communication are twofold: first to draw attention to current practice,
and secondly and more importantly, to provide a principled methodology for incorporating uncertainty into
analyses using historical estimates. Given the structure of the statistical problem we investigate various ways
of doing so. The resulting methods are compared in terms of the precision of any estimated function of the
model parameters and a preference order among them is established.
The paper is organized as follows. Our notation and formulation are outlined in Section 2. Section 3
provides our main theoretical findings which include the limiting distributions of the estimates in the presence
of historical data and a comparison thereof. In Section 4 two applications are described in conjunction with
accompanying numerical experiments. The first application addresses the two–way analysis of variance
(ANOVA) problem introduced in Section 2. The second, related application, deals with a drug interaction
study within the framework of Bliss–independence (Bliss, 1939), an old concept which has garnered much
recent attention. We conclude with a discussion in Section 5. All proofs are collected in an Appendix.
2. Notation and formulation
Consider a designed experiment or observational study, denoted by S, in which data D of size n is
observed. Suppose further that the model describing the distribution of D is indexed by ωT = (θT ,ηT )
where θ ∈ Rp and η ∈ Rq is the concatenation of η1 ∈ Rq1 , . . . ,ηK ∈ RqK with q = q1 + · · · + qK . Let
Φ(ω) be some function of the model parameters which is of interest to the researchers. Clearly Φ(ω) may
be a function of θ alone, η alone or of both θ and η. The primary goal of the study S, which we refer to
as the current study, is inference on Φ(ω) in the presence of historical data which we view as a collection of
K, independent estimators η̂1, . . . , η̂K obtained from historical studies S1, . . . ,SK of sizes m1, . . . ,mK and
m = m1 + · · ·+mK denotes the total sample size in the historical studies.
In some circumstances the statistical model for D may not be sufficient to identify ω but would allow the
estimation of θ if η were known in advance (e.g. Kronick et al., 2009). In other circumstances given the data
D both θ and η are estimable (e.g., Peddada et al., 2007). Thus, in this communication we consider two
distinct settings, the second of which has two variants. In the first setting, referred to as a Type I Problem,
only the parameter θ is estimated using the data D, while (η1, . . . ,ηK) are fixed at their historical estimated
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values (η̂1, . . . , η̂K). In the second setting, referred to as Type II Problem, a two–step procedure is utilized
to estimate θ while updating the estimators for (η1, . . . ,ηK). In some cases, although a Type II analysis
would be possible, the researcher may decide not to do so and apply a Type I analysis. One of our results
shows that this is an inferior strategy, i.e., if the data D identifies ω it is always advisable to re–estimate η.
It is also important to emphasize that there are situations in which the investigator, by means of the design
of the study S, may control whether the problem is of Type I or a Type II.
To fix ideas consider the two–way ANOVA model in which the expected value of an outcome Y is given
by
E(Y |T1, T2) = η0 + η1T1 + η2T2 + θT1T2 (1)
where Ti ∈ {0, 1} for i = 1, 2 indicates whether treatment i is administered. Here η0 denotes the mean of
Y when neither treatment is administered, ηi models the marginal increase in the expectation of Y when
treatment i is administered and θ models the interaction T1 × T2. Suppose, now that the historical data
consists of two studies S1 and S2 of sizes m1 and m2, respectively, where in the study Si treatment i was
compared with a control. Clearly the historical data provides no information on θ. Thus inference on θ
would require a new study S in which T1 = T2 = 1 for some subset of the observations. For simplicity,
interchangeability is assumed, i.e., all experimental units, in S1 and S2 as well as S, are assumed to be drawn
from the same population, e.g., Peddada et al. (2007), and therefore any change in the mean response may
be attributed solely to the treatment combination received. The assumption of interchangeability may be
relaxed as discussed in Section 5.
One objective of this communication is to provide a methodology for effective design and analysis of a
new study S of size n which allows the estimation of θ and utilizes the historical estimates of (η0, η1, η2)
obtained from S1 and S2. Depending on its objectives, the study S may be of various forms. For example,
one may choose to allocate all n observations to receive both treatments, i.e., T1 = T2 = 1. In this case
the data D is an IID sample of observations with mean η0 + η1 + η2 + θ and fixed variance σ2. Although
the parameter θ is not identifiable from D alone it is estimable given the historical data, so this is clearly
a Type I Problem. Alternatively, if S allocates observation to all treatment combinations then θ as well as
(η0, η1, η2) are estimable from S and this falls within the framework of a Type II Problem. This example will
be further analyzed in Section 4.1.
3. Results
Our main theoretical findings, i.e., Theorems 3.1, 3.2, and 3.4 describe the limiting distributions of
estimators for ω which are then compared in Theorems 3.3, 3.5 and 3.6.
3.1. Type I Problems
Suppose first that we are in the setting of a Type I Problem. Recall that in such circumstances only θ is
estimated while (η1, . . . ,ηK) are fixed at their historical values. Thus, let θ¯A solve
Ψ (θ, η̂) = 0 (2)
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where η̂ = (η̂T1 , . . . , η̂
T
K)
T . The estimating equation (2) may be a score equation motivated by likelihood
theory, a generalized estimating equation derived by quasi–likelihood or any other statistical estimation
framework. Observe that the solution θ¯A of (2) is obtained by plugging–in the sample values of the K
independent estimators η̂1, . . . , η̂K . For simplicity we may further assume that the data D is a random
sample Y1, . . . ,Yn and (2) is of the form
Ψ (θ, η̂) = n−1
n∑
i=1
ψ(θ, η̂,Yi).
The function ψ is assumed to be: (i) continuously differentiable with respect to both θ and η1, . . . ,ηK ; it
is further assumed to satisfy (ii) E0(ψ) = 0; (iii) E0(ψψ
T ) <∞; (iv) the matrix E0(∂ψ/∂η) exist; and (v)
the matrix E0(∂ψ/∂θ) exists and is invertible. Here E0(·) denotes the expectation taken at ω0 = (θ0,η0) =
(θ0,η1,0, . . . ,ηK,0), the true value of all parameters. Conditions (i)−(v) are all standard regularity conditions
often imposed in the literature (cf., Heyde 1997, Van der Vaart 2000). We now have the following:
Theorem 3.1. Let θ¯A be a solution to (2) and set η¯A = η̂. Assume that: (i) θ¯A is consistent at ω0; (ii)
the estimating function ψ satisfies the regularity conditions listed above; and (iii) the historical estimates
satisfy
√
mj(η̂j − ηj,0) ⇒ Nqj (0,Σj) and are independent of each other and of the current study. Then if
(m/mj)→ κj <∞ for all j = 1, . . . ,K as mj →∞ and n/m→ ρ ∈ (0,∞) as n→∞ we have
√
n(θ¯A − θ0, η¯A − η0)T ⇒ Np+q(0,A)
where
A =
(
Aθθ Aθη
Aηθ Aηη
)
with
Aθθ = (D
−1
θ0
)[Σψ + ρDη0ΣD
T
η0
](D−1θ0 )
T ,
Aθη = −ρ(Dθ0)−1Dη0Σ,
Aηη = ρΣ.
where Dθ0 = E0(∂ψ/∂θ), Dη0 = E0(∂ψ/∂η), Σψ = E0(ψψ
T ) and Σ = BlockDiag(κ1Σ1, . . . , κKΣK).
Remark 1. Clearly, Aθθ is the p×p asymptotic variance matrix of θ¯A, Aηη is the q×q asymptotic variance
matrix of η¯A and Aθη = A
T
ηθ is their p× q asymptotic covariance matrix.
The proof of Theorem 3.1 is a straightforward, but somewhat involved, application of the delta method.
In contrast with Randles (1982) and Pierce (1982) which describe the limiting distribution of statistics that
are explicit functions of estimated parameters the estimator θ¯A is an implicit function of η¯A. Further note
that (D−1θ0 )Σψ(D
−1
θ0
)T is the asymptotic variance of θ¯A when the true values of η1, . . . ,ηK are known in
advance. Thus the term
ρDη0ΣD
T
η0
may be viewed as the penalty for substituting estimators for the true values of the parameters. The penalty
may also be rewritten as ρ
∑K
j=1 κjDjΣjD
T
j whereDj = E0(∂ψ/∂ηj) which expresses its dependence on the
relative sample sizes, the asymptotic variances of the historical estimates and the sensitivity of the estimation
procedure with respect to the historical estimators, embodied in the matrices D1, . . . ,DK .
Remark 2. Note that if ρ is very small which occurs when m≫ n, then the penalty is inconsequential, i.e.,
that asymptotic variance of θ¯A is close to its variance when η1, . . . ,ηK are fully known.
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3.2. Type II Problems
Next, consider the case where both θ and η are estimable using the data D observed in the current study
S. In this case ω is estimated using a two step procedure. In the first step the data D is used to obtain the
pair (θ˜, η˜)T which simultaneously solve
Ψ (θ,η) = 0 and Γ (θ,η) = 0. (3)
The estimating equation Ψ is the estimating function for θ for fixed known value of η, as in Type I Problems,
whereas the estimating function Γ is the estimating function for η for fixed value of θ; it will not play any role
in our developments with the exception of Remark 6 appearing in the Appendix. Under standard regularity
conditions, cf., the conditions listed just before the statement of Theorem 3.1, the estimators (θ˜, η˜)T satisfy
√
n(θ˜ − θ0, η˜ − η0)T ⇒ Np+q(0,Υ ) (4)
where Υ is assumed to be a non–singular variance matrix which can be consistently estimated from the data
by, say Υ˜ , the standard sandwich estimator (Van der Vaart, 2000). For convenience we may partition Υ as
Υ =
Υθθ Υθη
Υηθ Υηη
 (5)
where Υθθ and Υηη denote the marginal asymptotic variances of θ˜ and η˜, respectively, and Υθη is their
asymptotic covariance. Naturally, a similar partition holds for Υ˜ . Furthermore, as in Section 3.1, at our
disposal are K independent historical estimators of η1, . . . ,ηK obtained using studies of sizes m1, . . . ,mK
which satisfy
√
mj(η̂j − ηj,0) ⇒ Nqj (0,Σj), where, again, it is assumed that Σj are non–singular and can
be consistently estimated for all j = 1, . . . ,K. Thus
√
m(η̂ − η0)⇒ Nq(0,Σ) (6)
where Σ is given in the statement of Theorem 3.1. Let Σ̂ be a consistent estimator of Σ.
The historic and current estimators of η can be aggregated, or combined, in many ways. Lemma 2,
appearing in the Appendix, suggests using the estimator
η¯ = (nΥ˜−1ηη +mΣ̂
−1)−1(nΥ˜−1ηη η˜ +mΣ̂
−1η̂) (7)
which is the MLE under normality assuming that the matrices Υηη and Σ are known. Note that
η¯ =W1η˜ +W2η̂ + op(1)
where the weightsW1 andW2 are the symmetric matrices
W1 = (γΥ
−1
ηη + (1 − γ)Σ−1)−1γΥ−1ηη and W2 = (γΥ−1ηη + (1− γ)Σ−1)−1(1 − γ)Σ−1 (8)
which satisfy I =W1+W2 with γ = lim(n/(n+m)). Thus (7) differs from the best linear unbiased estimator
by at most an op(1) term.
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In the second step we find θ¯B by solving
Ψ (θ, η¯) = 0. (9)
where η¯ is given by (7). We now have:
Theorem 3.2. Let θ¯B be a solution to (9) where η¯B = η¯ is given in (7). Assume that the regularity
conditions of Theorem 3.1 hold. Then
√
n(θ¯B − θ0, η¯B − η0)⇒ Np+q(0,B) (10)
where
B =
(
Bθθ Bθη
Bηθ Bηη
)
with
Bθθ = (D
−1
θ0
)[Σψ +Dη0(Υ
−1
ηη + (ρΣ)
−1)−1DTη0 ](D
−1
θ0
)T ,
Bθη = −D−1θ0 Dη0(Υ−1ηη + (ρΣ)−1)−1,
Bηη = (Υ
−1
ηη + (ρΣ)
−1)−1.
Although the mechanics are slightly more involved the proof of Theorem 3.2 builds on the proof of
Theorem 3.1. Moreover, the structure of the asymptotic variance matrices A and B are analogous with the
exception that the variance matrix ρΣ appearing in A is replaced with (Υ−1ηη + (ρΣ)
−1)−1 in B.
Remark 3. Observe that (Υ−1ηη + (ρΣ)
−1)−1 → 0 as ρ → 0 so the conclusions of Remark 2 hold here as
well.
It is clear that whenever the model for D identifies ω both (θ¯B, η¯B) and (θ¯A, η¯A) can be computed. Next,
using the concept of the Loewner order we show the former is superior to the latter. Recall that the matrix
V1 is said to be smaller in the Loewner order compared with the matrix V2 if V2−V1 is non–negative definite
(Pukelsheim, 2006). This relationship is denoted by V1  V2. Suppose now that V1 and V2 are the variances
of two (asymptotically) unbiased estimators. Then V1  V2 implies that the estimator associated with V1 is
more efficient than the estimator associated with V2. This means, for example, that the confidence ellipsoid
associated with V1 lies within the confidence ellipsoid associated with V2.
Theorem 3.3. Whenever the data D identifies ω we have
B  A. (11)
Moreover, for any function Φ we have V ΦB  V ΦA where V ΦA and V ΦB are the asymptotic variances of
Φ(θ¯A, η¯A) and Φ(θ¯B, η¯B) respectively.
Theorem 3.3 indicates that, if possible, it is always asymptotically beneficial to estimate both θ and η
using the data D collected in the study S. Moreover, Theorem 3.3 holds also when only a sub–vector of η is
identified by the data D.
Another variant of Type II Problems occurs when the data D is not available, but nevertheless the
estimators (θ˜, η˜) from the current study as well as their estimated variance, i.e., Υ˜ is given. The objective
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is then to combine the the current estimators (4) with the historical estimators (6). To this end we propose
estimating θ by
θ¯C = θ˜ − Υ˜θηΥ˜−1ηη (η˜ − η¯C) (12)
where η¯C = η¯ is given by (7). The estimators (7) as well as (12) are motivated by Lemma 2 and Remark 5
appearing in the Appendix.
Theorem 3.4. Let (θ¯C , η¯C)
T be defined by (7) and (12). Suppose further that (4) and (6) hold and both Υ
and Σ can be consistently estimated. Then as n→∞ we have
√
n(θ¯C − θ0, η¯C − η0)T ⇒ Np+q(0,C)
where C =MVMT with
V =
(
Υ 0
0 ρΣ
)
and M =
(
I −RW2 RW2
0 W1 W2
)
. (13)
The matrices W1 and W2 are defined in (8) and R = ΥθηΥ
−1
ηη . Moreover, we have:
Cθθ = Υθθ − ΥθηΥ−1ηηW2Υ Tθη,
Cθη = ΥθηW1
Cηη = (Υ
−1
ηη + (ρΣ)
−1)−1.
Theorem 3.4 describes the large sample behaviour of the estimators (7) and (12). Further insight is
facilitated by considering the simplest possible situation, i.e., when (θ, η) ∈ R2, in which case √m(η̂− η0)⇒
N (0, σ2) for the historical data, whereas for the current study √n(θ˜ − θ0, η˜ − η0)T ⇒ N (0,Υ ) where
Υ =
υ2θθ υθη
υθη υ
2
ηη
 .
It is not hard to see that (12) reduces to θ¯ = θ˜ − (υ˜θη/υ˜2ηη)(η˜ − η¯) where η¯ = w∗1 η˜ + w∗2 η̂ with
w∗1 =
n/υ˜2ηη
n/υ˜2ηη +m/σ̂
2
and w∗2 =
m/σ̂2
n/υ˜2ηη +m/σ̂
2
.
Furthermore Cθθ simplifies to
υ2θθ −
υ2θη
υ2ηη
w2 = υ
2
θθ(1− w2r2), (14)
where r = υθη/(υθθυηη) is the asymptotic correlation between θ˜ and η˜ and
w2 =
(1− γ)/σ2
γ/υ2ηη + (1− γ)/σ2
is the limiting value of w∗2 as n/(n +m) → γ. It follows that the asymptotic relative efficiency of θ¯ to θ˜ is
1− w2r2, which is at most unity (when υθη = 0) and no less than 1− r2 (when γ is close to 0). Clearly, the
historical estimates are useful only if the covariance υθη is non–zero and highly useful whenever w2 is close
to unity. A similar but more involved analysis applies when the parameters are multidimensional.
We emphasize that the structure of the estimators η¯C and θ¯C as well as the form of C are related to, but
much more general, than results obtained in the literature on both double sampling and monotone missing
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normal data (Andersen 1957, Morrison 1971, Kanda and Fujikoshi 1998). Double sampling is a widely
used technique in survey sampling, where the estimator is also known as the generalized regression estimator
(Thompson, 1997), as well as in other applications, cf. Davidov and Haitovsky (2000), Chen and Chen (2000)
and the references therein. We also note that equation (14) is a generalization of the formulas obtained for
the usual double sampling estimator (e.g., Tamhane 1978) where w2 = m/(n+m). The following Theorem
substantially generalizes on results obtained in the literature on both the double sampling and monotone
missing data.
Theorem 3.5. We have
C  Υ (15)
Moreover, for any function Φ we have V ΦC  V ΦΥ where V ΦC and V ΦΥ are the asymptotic variances of
Φ(θ¯C , η¯C) and Φ(θ˜, η˜) respectively.
In words, the estimator (θ¯C , η¯C), incorporating the historical estimates and derived by combining (θ˜, η˜)
and η̂, is more precise than (θ˜, η˜), the estimator based only on the current study.
Remark 4. It is also important to emphasize that in finite, typically small samples, the estimator Cθθ
may be in fact inferior to Υθθ. This typically occurs when the ”regression matrix” R, see the statement of
Theorem 3.4, is poorly estimated. This feature has been also recognized in the double sampling literature
(Tamhane 1978).
A little algebra shows that
Cθθ = Υθθ − ΥθηΥ−1ηη (Υ−1ηη + (ρΣ)−1)−1(ρΣ)−1Υ Tθη,
Cθη = ΥθηΥ
−1
ηη (Υ
−1
ηη + (ρΣ)
−1)−1
Cηη = (Υ
−1
ηη + (ρΣ)
−1)−1.
so we can remove the dependence of C on the matrices W1 and W2.
Clearly, whenever the data D is available both (θ¯B, η¯B) and (θ¯C , η¯C) can be calculated where η¯B = η¯C
are given in (7). Recall that θ¯B solves Ψ (θ, η¯) = 0 where Ψ (θ,η) = n
−1
∑n
i=1ψ(θ,η,Yi). Similarly, we
can view θ¯C as a solution to (some) estimating equation Λ(θ, η¯) = 0 where Λ(θ,η) = n
−1
∑n
i=1 λ(θ,η,Yi).
The form of Λ can be easily deduced from Lemma 2 and that of λ by plugging in the influence functions
for θ˜ and η˜ into Λ. In fact, the precise form of the influence function of θ¯C is readily derived, for more
details see Remark 6 appearing in the Appendix. It is worth noting that Ψ operates on the full data D
whereas Λ operates on functions thereof namely the estimators (θ˜, η˜) and η̂. Thus (θ¯C , η¯C) can be viewed
as functions of a coarsening of the data D and therefore is expected to be less efficient than (θ¯B, η¯B). This
indeed is the case under mild regularity conditions. A formal statement requires the introduction of some
additional notation. Let h = h(θ,η,Y ) denote any estimating function and denote Dθ0(h) = E0(∂h/∂θ)
and Dη0(h) = E0(∂h/∂θ). Note that earlier we referred to Dθ0(ψ) and Dη0(ψ) simply as Dθ0 and Dη0 .
Now:
Theorem 3.6. Suppose that the both ω¯B and ω¯C can be obtained. If
Dθ0(ψ)
−1Dη0(ψ) ≤ Dθ0(λ)−1Dη0(λ) (16)
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component–wise and
(Dθ0(ψ)
−1)E0(ψψ
T )(Dθ0(ψ)
−1)T  (Dθ0(λ)−1)E0(λλT )(Dθ0(λ)−1)T (17)
in the Loewner order, then
B  C. (18)
Moreover, for any function Φ we have V ΦB  V ΦC where V ΦB and V ΦC are the asymptotic variances of
Φ(θ¯B, η¯B) and Φ(θ¯C , η¯C) respectively.
Condition (17) holds when the estimating equation Ψ (θ,η0) = 0 results in more efficient estimators for
θ than those resulting from Λ(θ,η0) = 0 when η = η0 is set to its true value. This condition holds for
any sensibly choice of Ψ . In particular it holds for the score equations associated with maximum likelihood
estimation. Condition (16) roughly means that Ψ is less sensitive to small perturbations in both θ and η
compared with Λ. Conditions (16) are (17) are not necessary. For example, the conclusion of Theorem 3.6
may hold if ψ is more sensitive to small perturbations but at the same time much more efficient. We believe
that the aforementioned conditions hold broadly and the estimators (θ¯C , η¯C), described in Theorem 3.4, is
generally less efficient than (θ¯B, η¯B), described in Theorem 3.2. For an additional discussion see Remark 6
in the Appendix.
There are, however, situations in which B = C and situations where ω¯B = ω¯C for any data D. As we
shall see in the next section this is the case in normal linear models in which the estimators (θ˜, η˜) and η̂ are
actually sufficient statistics. Finally, it is worth noting that if Υθη = 0 then the estimator (θ¯C , η¯C) does not
improve θ˜ whereas there is always an improvement when the full data D is available.
4. Illustrations, applications and numerical results
In this section two applications are discussed in detail. In Section 4.1 the two–way ANOVA problem
introduced in Section 2 is investigated. In particular, various design options for the current study S are
evaluated. It is worth noting that although the abovementioned ANOVA problem is among the simplest
possible, its analysis is far from trivial. Next, in Section 4.2 we discuss the use of historical estimates in the
design of drug interaction studies in the context of Bliss independence. A simple algorithm for the design of
such studies is proposed.
4.1. Two way ANOVA
Recall the ANOVA model of Section 2 where the studies S1 and S2 were designed to estimate η1 =
(η0, η1)
T and η2 = (η0, η2)
T , respectively. Note that the parameter η0 is estimated in both studies so η1
and η2 are not distinct. Therefore employing any of the aforementioned findings requires the aggregation
of the historical estimates as if they came from a single experiment. The historical studies result in the
estimates (η̂0(S1), η̂1(S1)) and (η̂0(S2), η̂2(S2)) as well as their standard errors, we can easily back calculate the
potentially unobserved sufficient statistics and sample sizes in the studies S1 and S2 and estimate (η0, η1, η2)
by:
η̂1 = Y¯1(S1)− η̂0, η̂2 = Y¯2(S2)− η̂0, and η̂0 = m1,0Y¯0(S1) +m2,0Y¯0(S2)
m1,0 +m2,0
, (19)
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where the quantity Y¯j(Si) is the average response on treatment j ∈ {0, 1, 2} in study i ∈ {1, 2}. Similarly
mi,j is the size of of treatment group j in study i. It follows, under the usual conditions, that
√
m(η̂0 − η0, η̂1 − η1, η̂2 − η2)T ⇒ N (0,Σ),
for some matrix Σ. Furthermore, if (1) is homoscedastic model with variance σ2 and m1,0 = m1,1 = m2,0 =
m2,2, i.e., the studies S1 and S2 are balanced and of the same size, then it is easy to see that
Σ = σ2

2 −2 −2
−2 6 2
−2 2 6
 .
We will now investigate various designs for a new study S. If the primary focus of S is inference on θ then
it may, in some circumstances, be advantageous to allocate all n observations to the treatment arm receiving
both treatments one and two, i.e., T1 = T2 = 1 for all observations. This is clearly a Type I problem since ω
is not identifiable from D but given η the parameter θ is estimable. Note that an unbiased estimate for θ is
θ¯A = Y¯12(S) − (η̂0 + η̂1 + η̂2) (20)
and it is not hard to see that (20) solves (2) when ψ(θ, η0, η1, η2, Yi) = Yi − η0− η1− η2− θ. Thus, Σψ = σ2,
Dθ0 = 1 and Dη0 = −(1, 1, 1) and it follows that Aθθ, the asymptotic variance of (20) as described in
Theorem 3.1, reduces to
σ2 × (1 + 10ρ) where ρ = lim n
m
.
The second term appearing in the parentheses in the above display is an inflation factor, i.e., the price
to pay for substituting estimators for the unknown value of (η0, η1, η2). Note that when n/m → 0 as both
m → ∞ and n → ∞ the asymptotic variance of θ¯A approaches σ2. In practice this requires a large current
study and even larger historical data. Incidentally, since θ¯A is a linear function of Y¯12(S) and (η̂0, η̂1, η̂2) it
is not hard to see that its exact variance is σ2(1/n+ 10/m) which coincides with the asymptotic form.
Alternatively, suppose that the study S allocates n/4 observations to all treatment combinations. In this
case the data D identifies ω = (θ, η0, η1, η2)T , so this is a Type II problem. The usual estimators for this
design are η˜0 = Y¯0(S), η˜1 = Y¯1(S) − Y¯0(S), η˜2 = Y¯2(S)− Y¯0(S) and
θ˜ = Y¯12(S) − (Y¯1(S) + Y¯2(S)) + Y¯0(S)
and thus the limiting variance of (θ˜, η˜)T is
Υ = σ2

16 4 −8 −8
4 4 −4 −4
−8 −4 8 4
−8 −4 4 8
 .
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Next we aggregate the historical and current estimators for η. As in Section 3 we estimate η by η¯ =
W1η˜ +W2η̂ where
W ∗
1
= (nΥ−1ηη +mΣ
−1)−1nΥ−1ηη and W2∗ = (nΥ−1ηη +mΣ−1)−1mΣ−1.
Note that the weight matrices are functions of the variances Υηη and Σ as well as the ratio n/(n+m). Since
D is fully available to us then we can estimate θ by
θ¯B = Y¯12(S) − (η¯0 + η¯1 + η¯2). (21)
Note that the estimators (20) and (21) are of the same functional form. Further note that the statistic Y¯12
in (21) is a function of the n12 observations Y1, . . . , Yn12 receiving the treatment combination T1 = T2 = 1.
A straightforward calculation shows that Bθθ is given by
σ2 × (ξ−111 + 1T (Υ−1ηη + (ρΣ)−1)−11) where ρ = lim
n
m
,
where ξ11 is the fraction of the observations which are assigned to receive both treatments. In situations where
the full data is not available to us but (θ˜, η˜0, η˜1, η˜2) are known we may estimate θ by θ¯C = θ˜−ΥθηΥ−1ηη (η˜− η¯).
It can be verified that in this application, in which a normal linear model is involved and all estimators are
functions of sufficient statistics, the estimators θ¯B and θ¯C coincide. Therefore θ¯C is not discussed any further.
Table 1 provides a comparison of the asymptotic variances of (20) and (21) for a range of values of m
and n.
Table 1 Comes Here.
Table 1 displays asymptotic variances; the variances themselves are found by dividing any entry in the
table by the size of the current study in the relevant row. Observe that both Aθθ and Bθθ decrease as a
function of m for any fixed value of n and increase in n for any fixed m. For example when n = m = 100
Aθθ = 11 and Bθθ = 9.3 whereas when m = 100 and n = 5000 then Aθθ = 501 and Bθθ = 15.69 and when
m = 5000 and n = 100 then Aθθ = 1.2 and Bθθ = 4.2. Thus going down the first column of Table 1 the
asymptotic variance Aθθ is increases by a factor of approximately 45 whereas that of Bθθ by the much more
modest 1.4. Similarly going across the first row the asymptotic variances of Aθθ and Bθθ are reduced by a
factor of 9.2 and 2.2 respectively. Each pair (n,m) provides a direct comparison between the two designs
(design A, say, which assigns all experimental units in the current study to receive both treatments and
design B, say, which is a balanced design). Clearly, design A seems preferable in situations where m is much
larger that n, otherwise design B is to be preferred.
We now look a bit deeper into the question of optimal design. Suppose, that as before the historical
sample of size m where m1,0 = m1,1 = m2,0 = m2,2. The objective is to design a study S of size n
which would minimize the variance of the estimate of θ. Let ξij denote the proportion of observation who
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received treatment combination i × j where i and j are in {0, 1}. Thus the design vector is nothing but
ξ = (ξ00, ξ10, ξ01, ξ11). For simplicity we will assume an approximate design which implies that ξ lies in the
unit simplex. Moreover, estimating θ requires that ξ11 > 0. Note that Table 1 considers only designs with
ξ = (0, 0, 0, 1) and ξ = (1/4, 1/4, 1/4, 1/4). It is not hard to see that in this relatively simple setting the
optimal design (in the interior of the simplex) is attained when ξ−111 + 1
T (Υ−1ηη + (ρΣ)
−1)−11 is minimized
where
Υ = σ2

1
ξ00
+ 1ξ10 +
1
ξ01
+ 1ξ11
1
ξ00
−( 1ξ00 + 1ξ10 ) −( 1ξ00 + 1ξ01 )
1
ξ00
1
ξ00
− 1ξ00 − 1ξ00
−( 1ξ00 + 1ξ10 ) − 1ξ00 ( 1ξ00 + 1ξ10 ) 1ξ00
−( 1ξ00 + 1ξ01 ) − 1ξ00 1ξ00 1ξ00 + 1ξ10
 .
Symmetry consideration imply that under optimality ξ01 = ξ10 and since ξ00 = 1−2ξ10−ξ11 the minimization
involves only a two dimensional search. Table 2 provides the optimal design, i.e., the vector ξ for estimating
θ for various values of the ratio ρ = n/m found by a grid search with step 0.001 and the restriction that
ξ00 ≥ 0.02. This restriction is necessary; otherwise the matrix Υ can not be inverted.
Table 2 Comes Here.
The designs appearing in Table 2 are generally superior to those in Table 1. For example when ρ = 1 we
find that the asymptotic variances in Table 1 are 11.0 and 9.3 whereas the corresponding optimal asymptotic
variance given in Table 2 is 8.00. Further note that for large ρ, i.e., when n is larger than m, we find that
ξ01 = ξ10 = 1/4 and that the difference between ξ11 and ξ00 decreases in ρ. We believe that the balanced
design is optimal when ρ→∞. Also note that when ρ is smaller than a 1/4, i.e., when n is relatively small
to m, then ξ00 = 0.02, and ξ01 = ξ10 = 0.01 which are the smallest possible values allowed by our algorithm.
This suggest that further minor improvements are possible by setting ξ00 = 0 and/or ξ01 = ξ10 = 0. Clearly
when ξ01 = ξ10 = ξ00 we have a Type I Problem.
Therefore we next consider the situation that ξ00 = 0 and ξ01 = ξ10 > 0, in which case the current study
comprises of three groups and thus three group means: Y¯1(S), Y¯2(S) and Y¯12(S). It is important to note
that with these data alone we can not estimate ω. Nevertheless, the pair (Y¯1(S), Y¯2(S))T whose mean is
(η0+ η1, η0+ η2) can be aggregated with with η̂ the historical estimate of η. By an appropriate modification
of Lemma 2 it can be shown that η can be estimated by
η† = (nATV −1A+mΣ−1)−1(nATV −1S +mΣ−1η̂) (22)
where S = (Y¯1(S), Y¯2(S))T , V = σ2diag(ξ−101 , ξ−110 ) is its asymptotic variance and
A =
1 1 0
1 0 1
 .
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is the matrix which satisfies E(S) = Aη. Note that (22) is of the same form as (7) but with ATV −1A
instead of Υηη. Now, let θ¯D denote the solution to Ψ (θ,η
†) = 0 which is nothing but
θ¯D = Y¯12(S) − (η†0 + η†1 + η†2) (23)
A straightforward calculation shows that the asymptotic variance of θ¯D is given by
σ2 × (ξ−111 + 1T (ATV −1A+ (ρΣ)−1)−11) where ρ = lim
n
m
.
The formula above is useful in finding the optimal design for small values of ρ when ξ00 = 0. For example
when ρ = 1/8 then the design ξ = (0, 0.0005, 0.0005, 0.9990) results in a variance of 2.25 (actually 2.250751)
which is slightly smaller than 2.27 the reported variance in the first row of Table 2. Finally we note that
when ρ = 1/8 then Aθθ equals (precisely) 2.25 which means that in this application a design for Type I would
be the most effective.
4.2. Using historical estimates in drug interaction studies
This subsection deals with the optimal design of drug interaction studies. Consider two drugs D1 and
D2 with no–effect probabilities η1 and η2, respectively and let θ denote the no–effect probability when both
drugs are administered together. The drugs are called Bliss independent, see, Bliss (1939), Liu et al. (2018),
if
θ = η1η2. (24)
If (24) does not hold and θ < η1η2 there is synergy among the drugs, otherwise there is antagonism. The
concept of Bliss independence has seen a recent resurgence of interest as the need to asses the benefit of
combination therapies and drug–drug interactions has increased. Some current references are Pallmann and
Schaarschmidt (2016), Palmer and Sorger (2017), Russ and Kishony (2018), Qin et al. (2018) and Niu et al
(2019). Drug interaction studies are often carried out as single–dose experiment, e.g., Ansari et al. (2008),
where the interaction is assessed by considering a single dose of each of the two drugs. A more elaborate
design, which we will not consider here, assesses multiple drugs and doses using response surface methodology
as in Lee (2010).
Naturally, the quantity of interest in drug interaction studies is
Φ(θ,η) = log(θ) − log(η1)− log(η2). (25)
The formulation in (25) links the problem discussed here to the ANOVA setup considered earlier. In many
applications of single dose interaction tests, whether using historical data or not, an explicit or implicit
asymptotic argument is used, and the theoretical results for the asymptotic case presented above are relevant.
For example, Demidenko and Miller (2019) describes a Daphnia acute test with two stressors, single doses of
CuSO4 and of NiCl, where the numbers of surviving organisms in water were counted after 48 hours. The
observations reported were the surviving fractions of organisms only, without reporting their original numbers
thus, essentially, assuming their original numbers were very high, i.e., applying an asymptotic argument. But
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as pointed out by Pallmann and Schaarschmidt (2016), in single-dose experiments, correct statistical analysis
should rely on the observed frequencies, and not on the observed rates of success or failure. Therefore the
sample sizes used in each arm of the experiment are of crucial importance and in this subsection we provide
finite sample results.
For simplicity suppose that there exists historical estimates of η1 and η1 based on independent binomial
experiments with sizes m1 and m2. Suppose further that current study allows for the recruitment of n
experimental units, n1 of which will receiveD1, n2 will receiveD2 and n12 will receive both drugs. Obviously
n = n1 + n2 + n12 (26)
and θ can not be estimated unless n12 > 0. However it is possible that n1 = n2 = 0. The goal is to allocate
the experimental units optimally, which is equivalent to the problem of optimally allocating n + m1 +m2
observations in an experiment in which the single dose arms are no smaller than m1 and m2, respectively.
The optimal design problem can be approximated as the minimization of the large sample variance of of (25)
1
n12
1− θ
θ
+
1
n1 +m1
1− η1
η1
+
1
n2 +m2
1− η2
η2
, (27)
subject to the constraint (26).
In contrast with the design problem encountered in Section 4.1 the design criterion depends on the
unknown parameters, i.e., the probabilities θ and η. We propose allocating observations as if η1 = η̂1,
η2 = η̂2 and θ = η̂1η̂2 is equal to its estimated value under the hypothesis of Bliss independence.
One simple approach to the minimization of (27) is the following greedy iterative procedure, which
sequentially allocates observations into the condition where the variance is reduced most.
ALGORITHM
n12 ← 1, n1 ← 0, n2 ← 0
if n = n1 + n2 + n12 then
stop
else
R12(n12)← 1n12
1−η̂1η̂2
η̂1η̂2
R1(n1)← 1n1+m1
1−η̂1
η̂1
R2(n2)← 1n2+m2
1−η̂2
η̂2
C ← min{R12(n12 + 1)−R12(n12), R1(n1 + 1)−R1(n1), R2(n2 + 1)−R2(n2)}
if C = R12(n12 + 1)−R12(n12) then
n12 ← n12 + 1
end if
if C = R1(n1 + 1)−R1(n1) then
n1 ← n1 + 1
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end if
if C = R2(n2 + 1)−R2(n2) then
n2 ← n2 + 1
end if
end if
For example, if m1 = 30, m1 = 50, η̂1 = 0.7 and η̂2 = 0.8, the first 55 observations would be put in the
arm where both treatments administered, before the 56th observation would be used to improve the estimate
of ηˆ1. Table 3 contains a tabulation of the optimal allocation of (n12, n1, n2). For selected combinations of
the values of m1, m2, η1, η2 the table gives the minimal value of n, denoted as nmin, for which replications
of the historic observations is needed, and then the optimal allocation for nmin. As one would expect, when
θ is closer to 0.5 than η1 or η2, a larger sample size n12 is allocated in the optimal design to estimating θ,
than m1 or m2. In the opposite case, n12 is smaller than m1 or m2.
Table 3 Comes Here.
5. Summary and discussion
Historical findings often inspire current research whether or not they formally incorporate historical data
or estimates. Even when historical data or estimates are explicitly incorporated in the analysis, which is quite
common in practice, the variability of these estimates is rarely properly accounted for in the analysis. Relying
on historical estimates is particularly important when they are essential for model fitting but impossible, or
very expensive, to obtain in the context of a current study. A partial list of examples, drawn from the scientific
literature, was furnished earlier; many more exist. However, it is very difficult to find published research
where the details are given to the extent which would make the replication of the analysis possible. This
limits one’s ability to apply the results of this paper to published research. However, the results presented
here will inform future researchers of the scope and use of historical estimates and provide a tool kit for doing
so. We also hope that our investigation may have an effect on publication standards.
Different disciplines exhibit different modes of using historical data. Social scientists often incorporate
estimates from surveys in the process of model fitting, whereas biologists and engineers may use parameters
estimated in experiments which are very different than their own. One way, of course, of incorporating
historical estimates is using prior distributions within the Bayesian framework. For recent examples see Hoff
(2019) and Bryan and Hoff (2020). Our approach, however, is frequentist, as are most of the applications in
the literature. In particular, we show how to incorporate historical estimates in scenarios which we classify
at Type I Problems, where the historical parameters are not reestimated, and Type II Problems, where they
are. Two variants of Type II problems are described. See Theorems 3.1, 3.2 and 3.4. We also show that if,
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given the data D, it is possible to reestimate the historical parameters then it is beneficial to do so at least
for large sample sizes (Theorem 3.3). Other preference relations, in fact a hierarchy, among the estimators
and any function thereof, were also established, cf. Theorems 3.5, 3.6. It was also demonstrated that the
availability of historical data should be taken into account when an optimal experiment is designed. In
particular, relevant methods for a two–way ANOVA and for testing drug interaction were discussed.
In our analysis we have assumed that the the data D is a random sample and that the estimating equation
(2) is of an additive form. These assumptions have been used merely to simplify the exposition and are easily
modified to dependent data and various other estimating functions. It is clear that Type I and II Problems
describe a broad range of possibilities, nevertheless they are insufficient for describing the rich collection
of problems in which historical estimates may play a role. For example, our formulation assumes that the
historical parameters η1, . . . ,ηK are distinct. However, in many situations this is not so. In fact, some of
the historical studies may be full or partial replicates of each other. In cases when the current study is a
partial replicate of a historical study, simple plug-in methods or reestimation methods may be used. One
has to be careful, though, about the choice of the estimates. We are aware of situations where a simple
plug–in estimator performs better than a less than optimal reestimating method. Throughout, we have
assumed interchangeability. Clearly there are many experimental settings, especially in the sciences, where
this assumption is realistic. In other situations, say clinical trials, heterogeneity rather than interchangeability
is the rule. In such cases some modification of the methods proposed, using random effect models, may be
possible. See Rukhin (2007) and the references therein.
Finally, it is also worth mentioning that the problem of accounting for historical estimates is naturally
related, for obvious reasons, to sequential analysis, where data is collected over time, to meta–analysis,
where the effort is to combine information from different sources and double sampling, and especially non–
nested double sampling (Hidiroglou, 2001), which attempts to provide better inferences by augmenting and
predicting unobserved quantities from existing data sets. The literature on combining surveys (Kim and
Rao, 2012) is also relevant. Further understanding can be possibly attained by incorporating ideas from
these fields.
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Tables
m 100 200 500 1000 2000 5000
n Aθθ Bθθ Aθθ Bθθ Aθθ Bθθ Aθθ Bθθ Aθθ Bθθ Aθθ Bθθ
100 11.0 9.3 6.0 7.5 3.0 5.7 2.0 4.9 1.5 4.5 1.2 4.2
200 21.0 11.33 11.0 9.33 5.0 6.95 3.0 5.70 2.0 4.92 1.4 4.39
500 51.0 13.52 26.0 11.94 11.0 9.33 6.0 7.47 3.5 6.04 2.0 4.39
1000 101.0 14.61 51.0 13.52 21.0 11.3 11.0 9.33 6.0 7.47 3.0 5.70
2000 201.0 15.26 101.0 14.61 41.0 13.07 21.0 11.33 11.0 9.33 5.0 6.95
5000 501.0 15.69 251.0 15.4 101.0 14.61 51.0 13.52 26.0 11.94 11.0 9.33
Table 1: Asymptotic variances for θ for Type I and Type II Problems (with a balanced design) as function of the sizes of the
the historical and current studies
Sampling Ratio (ρ) Minimal Variance Bθθ Optimal Design (ξ)
1/8 2.27 (0.020, 0.001, 0.001, 0.978)
1/4 3.51 (0.020, 0.001, 0.001, 0.978)
1/2 5.53 (0.020, 0.160, 0.160, 0.660)
1 8.00 (0.020, 0.243, 0.243, 0.494)
2 10.66 (0.125, 0.250, 0.250, 0.375)
4 12.80 (0.187, 0.250, 0.250, 0.313)
8 14.22 (0.219, 0.250, 0.250, 0.281)
Table 2: Optimal design for Type II problems as a function of the sampling ratio ρ
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m1 m2 nmin n12 n1 n2 m1 m2 nmin n12 n1 n2
(η1, η2) = (0.3, 0.3) (η1, η2) = (0.5, 0.7)
10 10 23 22 1 0 10 10 15 14 1 0
20 10 23 22 0 1 10 20 15 14 1 0
30 10 23 22 0 1 10 30 15 14 1 0
20 10 23 22 0 1
(η1, η2) = (0.3, 0.5) 30 10 23 22 0 1
10 10 17 16 1 0 (η1, η2) = (0.5, 0.9)
20 10 26 25 0 1
30 10 27 26 0 1 10 10 13 12 1 0
10 20 17 16 1 0 10 20 13 12 1 0
10 30 17 16 1 0 10 30 13 12 1 0
20 10 24 23 1 0
(η1, η2) = (0.3, 0.7) 30 10 35 34 1 0
10 10 14 13 1 0 (η1, η2) = (0.7, 0.7)
10 20 14 13 1 0
10 30 14 13 1 0 10 10 17 16 1 0
20 10 28 27 1 0 20 10 17 16 0 1
30 10 32 31 0 1 30 10 17 16 0 1
(η1, η2) = (0.3, 0.9) (η1, η2) = (0.7, 0.9)
10 10 12 11 1 0 10 10 18 17 1 0
10 20 12 11 1 0 20 10 25 24 1 0
10 30 12 11 1 0 30 10 25 24 0 1
20 10 23 22 1 0 10 20 13 12 1 0
30 10 34 33 1 0 10 30 13 12 1 0
Table 3: The minimal sample size nmin, at which optimal allocation requires to repeat historical observations, for selected
values of the and no-success probabilities η1, η2 and historical sample sizes m1, m2 in a test of drug interaction.
Appendix: Proofs
Proof of Theorem 3.1:
Proof. Since θ¯A solves (2) we have
Ψ (θ¯A, η̂) = 0. (28)
By assumption ψ is continuous and differentiable with respect to θ and η1, . . . ,ηK . Thus, so is Ψ . Hence,
by the mean value theorem
Ψ (θ¯A, η̂) = Ψ (θ0, η̂) +
∂
∂θ
Ψ (θ0, η̂)(θ¯A − θ0) + o(||θ¯A − θ0||).
Applying the mean value theorem to Ψ (θ0, η̂) in the display above yields
Ψ (θ0, η̂) = Ψ (θ0,η0) +
∂
∂η
Ψ (θ0,η0)(η̂−η0) + o(||η̂ − η0||),
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so (28) can be rewritten as
Ψ (θ0,η0) +
∂
∂η
Ψ (θ0,η0)(η̂ − η0) + ∂
∂θ
Ψ (θ0, η̂)(θ¯A − θ0) +R = 0
where, assuming consistency R = o(||θ¯A − θ0||) + o(||η̂ − η0||) = op(1). Now, by the continuous mapping
theorem and the law of large numbers we have:
∂
∂θ
Ψ (θ0, η̂) =
1
n
n∑
i=1
∂
∂θ
ψ(θ0, η̂,Yi)
=
1
n
n∑
i=1
∂
∂θ
ψ(θ0,η0,Yi) + op(1) = E0(∂ψ/∂θ) + op(1)
which is a p× p matrix. Similarly,
∂
∂η
Ψ (θ0,η0) =
1
n
n∑
i=1
∂
∂η
ψ(θ0,η0,Yi) = E0(∂ψ/∂η) + op(1),
which is a p × q matrix. For convenience we set Dθ0 = E0(∂ψ/∂θ) and Dη0 = E0(∂ψ/∂η). Hence we can
reexpress (28) more concisely as
Ψ (θ0,η0) +Dη0(η̂ − η0) +Dθ0(θ¯A − θ0) + op (1) = 0
from which it follows, by the invertability of Dθ0 , that
√
n(θ¯A − θ0) = −D−1θ0 {
1√
n
n∑
i=1
ψ(θ0,η0,Yi) +
√
n√
m
Dη0
√
m(η̂ − η0)} + op (1) . (29)
Since the first term in the curly brackets above is a function of the data D collected in S and the second
term depends on the historical data, i.e., the studies S1, . . . ,SK the two terms are independent. Now, by the
central limit theorem
1√
n
n∑
j=1
ψ(θ0,η0,Yi)⇒ Np(0,Σψ)
where Σψ = E0(ψψ
T ). By assumption
√
mj(η̂j − ηj,0) ⇒ Nqj (0,Σj) for each j. Thus
√
m(η̂ − η0) ⇒
Nq(0,Σ) where Σ = BlockDiag(κ1Σ1, . . . , κKΣK) with κj = lim(m/mj) for j = 1, . . . ,K. Thus,
√
n√
m
Dη0
√
m(η̂ − η0)⇒ Np(0, ρDη0ΣDTη0). (30)
Collecting terms shows that
√
n(θ¯A − θ0) ⇒ Np(0,Aθθ) where Aθθ is as stated. Now, recall that η¯A = η̂.
Thus, marginally
√
n(η¯A − η0) ⇒ Nq(0, ρΣ), so Aηη = ρΣ. Clearly the joint asymptotic distribution of√
n(θ¯A − θ0, η¯A − η0)T , is also multivariate normal. Thus,
Aθη = lim
n
Cov(
√
n(θ¯A−θ0),
√
n(η¯A−η0)) = lim
n
[−D−1θ0 Dη0Cov(
√
n(η¯A−η0),
√
n(η¯A−η0))] = −ρD−1θ0 Dη0Σ,
as required, completing the proof.
Proof of Theorem 3.2:
Proof. Since θ¯B solves (9) where η¯ is given in (7) we have
Ψ (θ¯B, η¯) = 0. (31)
Following the derivations in the proof of Theorem 3.1, but with η¯ instead of η̂, we find that (31) can be
rewritten as
Ψ (θ0,η0) +Dη0(η¯ − η0) +Dθ0(θ¯B − θ0) + op (1) = 0
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from which it follows, by the invertibility of Dθ0 , that
√
n(θ¯B − θ0) = −D−1θ0 {
1√
n
n∑
j=1
ψ(θ0,η0,Yi) +Dη0
√
n(η¯ − η0)} + op (1) . (32)
Now using (7) and (8) we find that
√
n(η¯ − η0) =
√
n(W1(η˜ − η0) +W2(η̂ − η0)) + op(1)
which we may substitute into (32) yielding
√
n(θ¯B−θ0) = −D−1θ0 {
1√
n
n∑
j=1
ψ(θ0,η0,Yi)+Dη0W1
√
n(η˜−η0)+Dη0W2
√
n
m
√
m(η̂−η0)}+op (1) . (33)
The three terms in the curly brackets in (33) satisfy:
1√
n
n∑
i=1
ψ(θ0,η0,Yi)⇒ Np(0,Σψ),
Dη0W1
√
n(η˜ − η0)⇒ Nq(0,Dη0W1ΥηηW T1 DTη0),
Dη0W2
√
n√
m
√
m(η̂ − η0)⇒ Nq(0, ρDη0W2ΣW T2 DTη0).
Now, since η˜ is a solution to (3) the quantity
√
n(η˜ − η0) may be expressed as
1√
n
n∑
i=1
ϕ(θ0,η0,Yi) + op(1)
for some function ϕ which is known as the influence function (cf. Van der Vaart, 2000). For more details see
Remark 6. It follows by the central limit theorem, that
1√
n
n∑
i=1
ψ(θ0,η0,Yi) and
1√
n
n∑
i=1
ϕ(θ0,η0,Yi)
are jointly multivariate normal, thus so are the first two terms in the curly brackets of (33). Moreover
the third term, which depends on the historical data is independent of the first two terms and normally
distributed. Now the covariance among the first two terms is
Cov(
1√
n
n∑
i=1
ψ(θ0,η0,Yi),
√
n(η˜ − η0)) = Cov(
n∑
i=1
ψ(θ0,η0,Yi), (η˜ − η0)) = Cov(nψ(θ0,η0,Y1), (η˜ − η0))
= E0(ψ(θ0,η0,Y1)n(η˜ − η0)) = E0(E0(ψ(θ0,η0,Y1)n(η˜ − η0)|Y1))
= E0(ψ(θ0,η0,Y1)E0(n(η˜ − η0)|Y1)).
However, by assumption η˜ is asymptotically unbiased and
√
n–consistent, i.e., E0(η˜) = η0 + b/n + o(1/n)
so E0(n(η˜ − η0)|Y1)) = nE0((η˜ − η0)) + o(1) = O(1). Plugging the latter into the above display shows
that covariance above converges to 0 as n → ∞. It now follows that all three terms appearing in (33) are
asymptotically independent.
Set η¯B = η¯ and observe that using (33) we have
√
n(η¯B − η0)⇒ Nq(0,Bηη) where
Bηη =W1ΥηηW
T
1 + ρW2ΣW
T
2 .
Since γ/(1 − γ) = ρ we may reexpress the weight matrices as W1 = (Υ−1ηη + (ρΣ)−1)−1Υ−1ηη and W2 =
(Υ−1ηη + (ρΣ)
−1)−1(ρΣ)−1. Now, using the fact that products of symmetric matrices commute and a bit of
algebra it can be shown that
Bηη = (Υ
−1
ηη + (ρΣ)
−1)−1.
Collecting terms shows that
√
n(θ¯B−θ0)⇒ Np(0,Bθθ) whereBθθ is as stated. The stochastic representation
(29) shows that the joint asymptotic distribution of
√
n(θ¯ − θ0, η¯ − η0) is also multivariate normal with
Cov(
√
n(θ¯B − θ0),
√
n(η¯B − η0)) = −D−1θ0 Dη0Cov(
√
n(η¯B − η0),
√
n(η¯B − η0))→ −D−1θ0 Dη0Bηη
as required, completing the proof.
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Proof of Theorem 3.3:
The following preliminary Lemma will be used.
Lemma 1. Let X1 and X2 be random vectors with variances V1 = V(X1) and V2 = V(X2) with V1  V2.
Then for any matrix A we have V(AX1)  V(AX2). As a consequence we also have V −11  V −12 .
Proof of Lemma 1:
Proof. Observe that
uTV(AX1)u = u
TAV1A
Tu = (ATu)TV1(A
Tu) = vTV1v  vTV2v = (ATu)TV2(ATu)
= uTAV2A
Tu = uTV(AX2)u.
for any vector u. The inequality vTV1v  vTV2v holds since V2−V1 is non–negative definite by assumption.
Thus V(AX1)  V(AX2) as claimed.
Now choose A = V
−1/2
1 V
−1/2
2 and note that
V(AX1) = (V
−1/2
1 V
−1/2
2 )V1(V
−1/2
1 V
−1/2
2 )
T = V −12
V(AX2) = (V
−1/2
1 V
−1/2
2 )V2(V
−1/2
1 V
−1/2
2 )
T = V −11 .
The equalities above hold since products of symmetric matrices commute. The inequality V −11  V −12 follows
immediately.
We now continue with the proof of Theorem 3.3:
Proof. Observe that A is the variance matrix of the random vector
T1 =
(−D−1θ0 −D−1θ0 Dη0
0 I
)(
S1
S2
)
where S1 ∼ Np(0,Σψ) and S2 ∼ Nq(0, ρΣ) are independent. Similarly, B is the variance matrix of the
random vector
T2 =
(−D−1θ0 −D−1θ0 Dη0
0 I
)(
S1
S3
)
where S1 ∼ Np(0,Σψ) and S3 ∼ Nq(0, (Υηη + (ρΣ)−1)−1 are independent. Now,
V
(
S1
S2
)
− V
(
S1
S3
)
=
(
0 0
0 ρΣ − (Υηη + (ρΣ)−1)−1
)
It is easy to verify that Υηη + (ρΣ)
−1  (ρΣ)−1 so by the second part of Lemma 1 we have ρΣ  (Υηη +
(ρΣ)−1)−1 and therefore
V
(
S1
S3
)
 V
(
S1
S2
)
.
Applying Lemma 1 we find that
B = V(T2)  V(T1) = A
as required.
Next, an application of the δ–method and Theorems 3.1 and 3.2 shows that
√
n(Φ(θ¯A, η¯A)−Φ(θ0,η0))⇒
Nr(0,PAP T ) and √n(Φ(θ¯B, η¯B) − Φ(θ0,η0)) ⇒ Nr(0,PBP T ) where r is the dimension of Φ and P =
E0(∂Φ/∂ω). Observe that PAP
T is the variance of the random vector PT1 whereas PBP
T is the variance
PT2. Since B  A it follows from Lemma 1 that PBP T  PAP T concluding the proof.
The following lemma motivates the use of the estimators (7) and (12)
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Lemma 2. Let W ∼ Nq(η,m−1Σ) and (U ,V )T ∼ Np+q((θ,η)T , n−1Υ ) be independent random vectors
where
Υ =
(
Υθθ Υθη
Υηθ Υηη
)
.
Then the MLEs of θ and η are
θ¯ = U − ΥθηΥ−1ηη (V − η¯) and η¯ = (nΥ−1ηη +mΣ−1)(nΥ−1ηη V +mΣ−1W ). (34)
Proof of Lemma 2:
Proof. The likelihood is given by
L(θ,η) = f(U ,V ; θ,η)f(W ;η)
= f(U |V ; θ,η)f(V ;η)f(W ;η).
Now U |V ∼ Np(λ,Λ) with
λ = E(U |V ) = θ + ΥθηΥ−1ηη (V − η),
Λ = V(U |V ) = n−1(Υθθ − ΥθηΥ−1ηη Υηθ),
so λ is linear in both θ and η. Thus we may reparameterize f(U |V ; θ,η) as f(U |V ;λ) where
f(U |V ;λ) ∝ exp{−1
2
(U − λ)TΛ−1(U − λ)}.
Also marginally V follows a Nq(η, n−1Υηη) distribution so
f(V ;η)f(W ;η) ∝ exp{−1
2
(V − η)TnΥ−1ηη (V − η)} exp{−
1
2
(W − η)TmΣ−1(W − η)}
It now follows that the MLEs for (λ,η) are
λ¯ = U ,
η¯ = (nΥ−1ηη +mΣ
−1)−1(nΥ−1ηη V +mΣ
−1U).
Thus by the invariance property of MLEs we find that the MLE of θ is
θ¯ = U − ΥθηΥ−1ηη (V − η¯)
which completes the proof.
Remark 5. To obtain the estimators the estimators (7) and (12) apply Lemma 2 and substitute θ˜ for U , η˜
for V and η̂ for W . Further substitute Υ˜ and Σ̂ for Υ and Σ, respectively.
Proof of Theorem 3.4:
Proof. First note that the difference η˜ − η¯C in (12) is a linear combination of η˜ and η̂ given by
(nΥ˜−1ηη +mΣ̂
−1)−1mΣ̂−1(η˜ − η̂).
Therefore,
(
θ¯C
η¯C
)
=
(
I −Υ˜θηΥ˜−1ηη (nΥ˜−1ηη +mΣ̂−1)−1mΣ̂−1 Υ˜θηΥ˜−1ηη (nΥ˜−1ηη +mΣ̂−1)−1mΣ̂−1
0 (nΥ˜−1ηη +mΣ̂
−1)−1nΥ˜−1ηη (nΥ˜
−1
ηη +mΣ̂
−1)−1mΣ̂−1
)θ˜η˜
η̂
 .
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Since Υ and Σ can be consistently estimated it follows that(
θ¯C
η¯C
)
=
(
I −ΥθηΥ−1ηη (nΥ−1ηη +mΣ−1)−1mΣ−1 ΥθηΥ−1ηη (nΥ−1ηη +mΣ−1)−1mΣ−1
0 (nΥ−1ηη +mΣ
−1)−1nΥ−1ηη (nΥ
−1
ηη +mΣ
−1)−1mΣ−1
)θ˜η˜
η̂
+ op(1).
Clearly, the fact that n/(n+m)→ γ implies that (nΥ−1ηη +mΣ−1)−1nΥ−1ηη →W1 and (nΥ−1ηη +mΣ−1)−1mΣ−1 →
W2 so we may rewrite the display above as(
θ¯C
η¯C
)
=M
θ˜η˜
η̂
+ op(1) (35)
whereM is given in (13). Further observe that
M
θ0η0
η0
 = (θ0
η0
)
(36)
and that √
n(θ˜ − θ0, η˜ − η0, η̂ − η0)⇒ Np+2q(0,V ) (37)
where V is given by (13). Now (35), (36) and (37) together imply that(
θ¯C − θ0
η¯C − η0
)
⇒ Np+q(0,MVMT ) (38)
as stated. In particular Cθθ is the appropriate submatrix ofMVM
T . Multiplying out we find that
Cθθ = Υθθ − ΥθηW2RT −RW2Υηθ +RW2ΥηηW2RT + ρRW2ΣW2RT . (39)
The matrices Υηη,Σ andW2 are symmetric and thus their products commute. It follows thatRW2ΥηηW2R
T
equals RΥηηW
2
2R
T and ρRW2ΣW2R
T equals ρRΣW 22R
T . It is also easy to verify that ΥθηW2R
T =
RW2Υηθ so
ΥθηW2R
T +RW2Υηθ = 2ΥθηW2R
T = 2RΥηηW2R
T .
Combining and simplifying we obtain
Cθθ = Υθθ −RΥηηSRT .
where
S = 2W2 −W 22 − ρW 22ΣΥ−1ηη . (40)
Now, using symmetry, standard algebraic manipulation and the fact that ρ = γ/(1− γ) we have
S = (γΥ−1ηη + (1− γ)Σ)−2{2(1− γ)Σ−1(γΥ−1ηη + (1− γ)Σ)− (1− γ)2Σ−2 −
γ
1− γΣΥ
−1
ηη (1 − γ)2Σ−2}
= (γΥ−1ηη + (1− γ)Σ)−2(1− γ)(γΥ−1ηη + (1− γ)Σ)
= (γΥ−1ηη + (1− γ)Σ)−1(1− γ)Σ−1 =W2
Thus Cθθ = Υθθ −RΥηηW2RT = Υθθ − ΥθηΥ−1ηηW2Υ Tθη as required. It is also clear that Cηη = Bηη and
that
Cθη = lim
n
Cov(
√
n(θ¯C − θ0),
√
n(η¯C − η0)) = lim
n
nCov(θ¯C , η¯C) = lim
n
nCov(θ˜ − R˜(η˜ − η¯), η¯)
= lim
n
n(Cov(θ˜, η¯)− R˜Cov(η˜ − η¯, η¯))
where R˜ = Υ˜θηΥ˜
−1
ηη . Now nCov(θ˜, η¯) = nCov(θ˜,W1η˜ +W2η̂ + op(1)) → ΥθηW1. Furthernote that
nCov(η˜ − η¯, η¯) = nCov(η˜,W1η˜ +W2η̂ + op(1))− nCov(η¯, η¯)→ ΥηηW1 − (Υ−1ηη + (ρΣ)−1)−1 = 0 since
ΥηηW1 = Υηη(γΥ
−1
ηη + (1 − γ)Σ−1)−1γΥ−1ηη = (Υ−1ηη + (ρΣ)−1)−1
where we have used the fact that ρ = γ/(1− γ). Thus Cθη = ΥθηW1 concluding the proof.
28
Proof of Theorem 3.5:
Proof. Suppose that (U ,V )T ∼ N ((θ,η)T ,Υ ) and W ∼ N (η, ρΣ) are independent. Let Iω(U ,V ) and
Iω(U ,V ,W ) denote the Fisher Information about ω = (θ,η)
T in (U ,V ) and (U ,V ,W ) respectively. It is
clear that Iω(U ,V ) = Υ
−1. Moreover, repeating the calculations in proofs of Lemma 2 and Theorem 3.4 we
deduce that Iω(U ,V ,W ) = C
−1. The additivity of Fisher’s Information implies that
Iω(U ,V ,W )  Iω(U ,V ). (41)
Equation (41) and Lemma 1 imply that
C  Υ
as stated. The fact that V ΦC  V ΦΥ now follows as in Theorem 3.3.
Proof of Theorem 3.6:
Proof. By Equation (32) in the proof of Theorem 3.2 we have
√
n(θ¯B − θ0) = −(Dθ0(ψ))−1{
1√
n
n∑
i=1
ψ(θ0,η0,Yi) +Dη0(ψ)
√
n(η¯ − η0)} + op (1) ,
and similarly,
√
n(θ¯C − θ0) = −(Dθ0(λ))−1{
1√
n
n∑
i=1
λ(θ0,η0,Yi) +Dη0(λ)
√
n(η¯ − η0)} + op (1) .
The analysis in the proof of Theorem 3.2 shows that in both equations above the terms in the curly brackets are
asymptotically independent. Conditions (17) and (16) immediately imply the conclusion of the Theorem.
By Equation (32) in the proof of Theorem 3.2
Remark 6. Recall that (θ˜, η˜) simultaneously solve Ψ (θ,η) = 0 and Γ (θ,η) = 0 where Γ (θ,η) = n−1
∑n
i=1 γ(θ,η,Yi).
Standard calculations show that(
θ˜
η˜
)
=
(
θ0
η0
)
+D−1
(
1
n
∑n
i=1 ψ(θ,η,Yi)
1
n
∑n
i=1 γ(θ,η,Yi)
)
+ op(1) (42)
where
D =
(
D11 D12
D21 D22
)
=
(
Dθ(ψ) Dη(ψ)
Dθ(γ) Dη(γ)
)
.
Using the above notations and rewriting Equation (32) we have
θ¯B = θ0 +
1
n
n∑
i=1
D−111 ψ(θ,η,Yi)−D−111 D12(η¯ − η0) + op(1). (43)
As demonstrated in the proof of Theorem 3.2 the two terms above are asymptotically independent so we can
re-express θ¯B as
θ¯B = θ0 +
1
n
n∑
i=1
{D−111 ψ(θ,η,Yi)−D−111 D12Qi}+ op(1) (44)
where Qi are IID N (0,W1ΥηηW T1 + ρW2ΣW T2 ) RVs which are independent of D. Furthernote that by
(42)
θ˜ = θ0 +D
11 1
n
n∑
i=1
ψ(θ,η,Yi) +D
12 1
n
n∑
i=1
γ(θ,η,Yi) + op(1),
η˜ = η0 +D
21 1
n
n∑
i=1
ψ(θ,η,Yi) +D
22 1
n
n∑
i=1
γ(θ,η,Yi) + op(1),
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where Dij is the appropriate submatrix of D−1. Substituting the formulas above into Equation (12) for θ¯C
and simplifying we find that
θ¯C = θ0+
1
n
n∑
i=1
{(D11−ΥθηΥ−1ηηD21)ψ(θ,η,Yi)+(D21−ΥθηΥ−1ηηD22)γ(θ,η,Yi)+ΥθηΥ−1ηηQi}+op(1). (45)
Therefore comparing the estimators θ¯B and θ¯C amounts to comparing their influence functions implicit in
(44) and (45), i.e.,
D−111 ψ(θ,η,Yi)−D−111 D12Qi
and
(D11 − ΥθηΥ−1ηηD21)ψ(θ,η,Yi) + (D21 − ΥθηΥ−1ηηD22)γ(θ,η,Yi) + ΥθηΥ−1ηηQi,
respectively. Also note that
Υ = (D−1)
(
E0(ψψ
T ) E0(ψγ
T )
E0(γψ
T ) E0(γγ
T )
)
(D−1)T
so although in principal it is possible to always compare the above influence functions in practice this com-
parison is very difficult unless some further simplifying assumptions are imposed.
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